$0.96
−2.62%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.95
From 52W high−59.30%
Volume23593.00
Market cap$7.72M
P/E (TTM)—
P/S (TTM)1.5x
Div yield—
Key dataOct 19, 2026
Open
$0.95
From 52W high
−59.30%
Volume
23593.00
Market cap
$7.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
31.1
MomentumView details →
1D Return
−2.62%
YTD Return
+22.65%
SummaryUpdated Jun 1, 2026
Immuron Limited (NASDAQ:IMRN) is an Australian-based biopharmaceutical company founded in 1994 that specializes in developing and commercializing polyclonal antibody therapies. The company went public on NASDAQ in 2017 and operates through two main segments: Research and Development, and Hyperimmune Products. Immuron focuses on gastrointestinal health solutions, leveraging its proprietary technology platform based on bovine colostrum with hyperimmune antibodies to create both over-the-counter products and prescription drug candidates.
Similar companies
Latest newsMore news →
Immuron Ltd announced that results from its Phase 2 trial of once-daily oral Travelan were published in Scientific Reports; the clinical data had previously been announced on March 7, 2024.7d agoImmuron Limited announced it has executed an exclusive distribution agreement with Calmino group AB to launch PROIBS in the United States, following its earlier launch of PROIBS in Australia during FY2026.46d ago